DiaMedica Therapeutics
MINNEAPOLIS, Minnesota, United States · Biopharma, Biotechnology, Health Care
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), is a clinical-stage biopharmaceutical company that is focused on developing novel treatments where there is significant unmet clinical need or where no current therapies are available, with the focus on acute ischemic stroke and preeclampsia.
Key facts
- Headquarters
- MINNEAPOLIS, Minnesota, United States
- Employees
- 38
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (DMAC)
- Website
- www.diamedica.com
- Company page
Recent activity at DiaMedica Therapeutics
- : SEC 8-K (2.02): On May 6, 2026, DiaMedica Therapeutics Inc. announced its condensed consolidated financial results for the quarter ended March 31, 2026. The report highlights financial performance metrics including revenue, expenses, and net income for the quarter, reflecting the company’s operational status and financial health. The press release is attached as Exhibit 99.1 and provides detailed insights that are integral to investors and analysts evaluating the company's performance. This filing is significant as it offers transparency into the company's financial condition and operational efficiency, impacting investor confidence and decisions.
- : SEC 8-K (8.01):
- : SEC 8-K (8.01):
- : DiaMedica Therapeutics
- : DiaMedica Therapeutics raised $30 million in a private placement to accelerate its preeclampsia and fetal growth restriction pipeline, led by current investors.
- : DiaMedica Therapeutics Inc. Publishes Research on DM199 for Treating Acute Ischemic Stroke in Journal Stroke
- : DiaMedica Therapeutics Inc. announces the dosing of the first patient in a Phase 2 trial of DM199 aimed at treating preeclampsia.
- : DiaMedica Therapeutics
- : DiaMedica Therapeutics Inc. raised $11.8 million in a private placement to fund clinical and product development activities for DM199 and for other working capital and general corporate purposes.
- : DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
DiaMedica Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Jul 2025 | Venture | $30.1M |
| Jul 2025 | Post-IPO Equity | $30.0M |
| Jul 2024 | Venture | $11.8M |
| Jun 2024 | Post-IPO Equity | $11.8M |
| Jun 2023 | Venture | $37.5M |
Leadership
- Zhenyu Xiao, Director
- James Parsons, Director
- Michael Giuffre, Director
- Richard Pilnik, Director
- Rick Pauls, Executive Officer, Director
- Rick Pauls, President
- Lorianne Masuoka, Chief Medical Officer
- Dominic Cundari, Executive Officer
- David Gurvey, Executive Officer
- Paul Papi, Executive Officer
- Scott Kellen, Executive Officer
- Todd Verdoorn, Executive Officer
Verified email and direct lines for DiaMedica Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
DiaMedica Therapeutics in the news
- DiaMedica Therapeutics Inc. (DMAC) Stock Price, News, Quote & History - Yahoo! Finance Canada (Oct 23, 2026)
- DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar - BioSpace (Oct 19, 2026)
- DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026 - Business Wire (Aug 04, 2026)
- DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences - Yahoo Finance (Sep 02, 2026)
- DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction - BioSpace (Jun 24, 2026)
- DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights - Business Wire (Aug 11, 2026)
- Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet - qz.com (Sep 08, 2026)
- DM199 (Rinvecalinase Alfa) Program Expanded by Diamedica Therapeutics into Preeclampsia - The Clinical Trial Vanguard (Jun 27, 2024)
Companies similar to DiaMedica Therapeutics
- Candel Therapeutics · Biopharma, Biotechnology, Health Care, Therapeutics
- Arecor Therapeutics PLC · Biopharma, Biotechnology, Health Care, Therapeutics
- Windward Bio · Biopharma, Biotechnology, Health Care, Therapeutics
- HCW Biologics · Biopharma, Biotechnology, Health Care, Therapeutics
- CASI Pharmaceuticals · Biopharma, Biotechnology, Health Care, Therapeutics
About DiaMedica Therapeutics: questions and answers
What does DiaMedica Therapeutics do?
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), is a clinical-stage biopharmaceutical company that is focused on developing novel treatments where there is significant unmet clinical need or where no current therapies are available, with the focus on acute ischemic stroke and preeclampsia.
Where is DiaMedica Therapeutics headquartered?
DiaMedica Therapeutics is headquartered in MINNEAPOLIS, Minnesota, United States.
How many employees does DiaMedica Therapeutics have?
DiaMedica Therapeutics has about 38 employees.
Has DiaMedica Therapeutics raised funding?
Yes. Fundz has recorded 5 funding events for DiaMedica Therapeutics. The most recent, $30.1M, was in Jul 2025.
Who leads DiaMedica Therapeutics?
Rick Pauls is a President at DiaMedica Therapeutics.
What is the latest news on DiaMedica Therapeutics?
On May 06, 2026, SEC 8-K (2.02): On May 6, 2026, DiaMedica Therapeutics Inc. announced its condensed consolidated financial results for the quarter ended March 31, 2026. The report highlights financial performance metrics including revenue, expenses, and net income for the quarter, reflecting the company’s operation
Is DiaMedica Therapeutics a public company?
Yes. DiaMedica Therapeutics is publicly traded under the ticker DMAC.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy